Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up

Abstract

Purpose To evaluate the safety and efficacy of intravitreal bevacizumab in Chinese patients with choroidal neovascularization (CNV) secondary to pathologic myopia. Methods Eight eyes of consecutive patients with myopic CNV without earlier treatment were treated with intravitreal injection of bevacizumab (2.5 mg). All patients underwent a clinical examination, which included visual acuity measurements, fundus photography, fluorescein angiography, and optical coherence tomography. Results Eight eyes of eight patients with ages ranging from 26 to 62 years (mean 41.5 years) were enroled. The follow-up period ranged from 13 to 17 months (mean, 14.9 months). At the 12-month follow-up, vision had improved in all eyes by three or more lines. However, a new-onset CNV adjacent to the earlier lesion and visual loss of one line at the 16th month were observed in one eye. The mean VA had significantly improved from the baseline value 20/82 to 20/25 (P ¼ 0.017). The final mean central retinal thickness was 214.1 ± 36.3 lm, with a mean decrease of 59.8 lm from the pretreatment value (P ¼ 0.017). The mean number of injections was 1.4 (ranging from 1 to 2) within 12 months. No other ocular or systemic side effects were noted. Conclusions In this small series of patients with 1-year follow-up, intravitreal injection of 2.5 mg bevacizumab seems to be effective and safe in patients with myopic CNV.

Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization

“…[9][10][11][12][13][14][15][16][17][18][19][20][21][22] However, the follow-up periods were up to 1-year in most of the earlier studies. There have been a few studies that showed 2-years visual outcomes of IVB for mCNV, and the results have been conflicting.…”

“…6 Because of the poor natural history of mCNVs, several procedures have been tried to treat mCNVs, for example, thermal laser photocoagulation, 7 photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis Pharma AG, Basel, Switzerland), 8 and intravitreal bevacizumab (Avastin; Genentech, South San Francisco, CA, USA), a recombinant humanized monoclonal anti-VEGF antibody. Earlier case series have reported good visual outcomes 1 to 2 years after intravitreal bevacizumab (IVB), [9][10][11][12][13][14][15][16][17][18][19][20][21] and at present IVB would be the first-line therapy for sub-and juxtafoveal mCNVs. 22 However, there is still not enough information to predict the visual outcome of each patient with mCNV treated with IVB.…”

Intravitreal bevacizumab for choroidal neovascularisation secondary to causes other than age-related macular degeneration

“…[21][22][23] Treatment outcomes after intravitreal bevacizumab in 15 studies are summarised in Table 1. [24][25][26][27][28][29][30][31][32][33][34][35][36][37][38] A cumulative analysis of all study data reveals the following trends. Of all studies examined, a total of 181 eyes received treatment for naïve lesions, and 74 eyes were treated earlier.…”

Avaliação dos Resultados do Tratamento Antiangiogénico na Neovascularização Coroideia Associada à Miopia Patológica

“…4,6,[21][22][23][24][25] A terapêutica antiangiogénica, nomeadamente o bevacizumab e o ranibizumab, estão aprovados para o tratamento da neovascularização coroideia secundária à degenerescência macular da idade (DMI), tendo também mostrado claros benefícios clínicos na neovascularização associada a outras situações de causa inflamatória ou vascular. 3,9,26 Face à evidência de eficácia e segurança com o uso destes agentes, a sua utilização na NVC associada à miopia patológica é atualmente considerada terapêutica de primeira linha. [2][3][4]11,26 O ranibizumab e o bevacizumab são anticorpos monoclonais antiangiogénicos utilizados no tratamento da neovascularização coroideia, com resultados favoráveis a curto prazo.…”

“…3,9,26 Face à evidência de eficácia e segurança com o uso destes agentes, a sua utilização na NVC associada à miopia patológica é atualmente considerada terapêutica de primeira linha. [2][3][4]11,26 O ranibizumab e o bevacizumab são anticorpos monoclonais antiangiogénicos utilizados no tratamento da neovascularização coroideia, com resultados favoráveis a curto prazo. 9,27 Estudos recentes demonstraram resultados benéficos e sustentados da terapêutica com bevacizumab na NVC miópica, 28,29 estando em curso ensaios clínicos randomizados e multicêntricos para avaliar a eficácia do ranibizumab a longo prazo.…”